Anumana vs MyoVista wavECG
For a cardiology clinic that wants AI-ECG results this year, HeartSciences is out of the running.
Its MyoVista wavECG, a 12-lead resting electrocardiograph, was cleared on October 5, 2026 without an AI algorithm, and the company says it does not intend to commercialize the device without one. The diastolic dysfunction algorithm it is developing is not cleared and carries no timeline. A pending business combination with Fortitude Mining Holdings is expected to close in the fourth quarter of 2026.
Anumana already has cleared ECG-AI for low ejection fraction, pulmonary hypertension and cardiac amyloidosis, running on standard 12-lead ECGs. A health system that wants a device-agnostic ECG management layer with third-party AI models is the buyer HeartSciences describes for MyoVista Insights, yet the vendor's footer says its AI-ECG products are not commercially available in the United States.
Decision support · Reviewed November 2, 2026
Anumana
by Anumana
ECG-AI software that flags low ejection fraction, pulmonary hypertension and cardiac amyloidosis from standard 12-lead ECGs.
MyoVista wavECG
by HeartSciences
12-lead resting ECG device for cardiology clinics, FDA 510(k) cleared in October 2026 without its AI-ECG algorithm.
When to pick each one
Anumana
- Cleared algorithms for three heart conditions
- Works on standard 12-lead ECGs already recorded
MyoVista wavECG
- 12-lead resting ECG device cleared October 2026
- Epic showroom listing
Score
Each row shows points earned of points available under the published rubric.
Anumana
37of 100
MyoVista wavECG
31of 100
| Dimension | Anumana | MyoVista wavECG | Difference |
|---|---|---|---|
| FDA clearance | 12 / 12 | 12 / 12 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 6 / 10 | -6 |
| EHR integrations (count) | 0 / 5.6 | 1.7 / 5.6 | -1.7 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 4.8 | 1.9 / 4.8 | -1.9 |
| Bidirectional write-back | 0 / 1.2 | 0 / 1.2 | 0 |
| Peer-reviewed papers | 14.7 / 21 | 0 / 21 | +14.7 |
| RCT / meta-analysis / systematic review | 0 / 9 | 0 / 9 | 0 |
| Funding & adoption signal | 3 / 12 | 3 / 12 | 0 |
| Pricing transparency | 1.3 / 2.5 | 1.3 / 2.5 | 0 |
| Years in market | 0 / 6 | 0 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
Anumana
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. The pricing page returns 404; the site offers a demo request only. |
MyoVista wavECG
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
Anumana
FDA decisions
K253801 (opens in new tab)510(k)2026-04-07
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm (1040)
K252360 (opens in new tab)510(k)2026-03-28
ECG-AI Pulmonary Hypertension (PH) 12-Lead algorithm (1020)
K250652 (opens in new tab)510(k)2025-07-28
ECG-AI Low Ejection Fraction (LEF) 12-Lead algorithm (1010)
K232699 (opens in new tab)510(k)2023-09-28
Low Ejection Fraction AI-ECG Algorithm
Peer-reviewed
3 PubMed records name Anumana.
- A Pragmatic Trial Evaluating the Impact of the Anumana Clinical Decision Support Tool for Guideline-Directed Management of Heart Failure (ACT-HF): Clinical trial design and methods. (opens in new tab)
- Comment on "A pragmatic trial evaluating the impact of the anumana clinical decision support tool for guideline-directed management of heart failure (ACT-HF): Clinical trial design and methods". (opens in new tab)
- Identification and risk stratification of coronary disease by artificial intelligence-enabled ECG. (opens in new tab)
MyoVista wavECG
FDA decisions
K260005 (opens in new tab)510(k)2026-10-05
MyoVista wavECG (DG-200-B15-003)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Anumana | MyoVista wavECG |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Epic |
| Founded | n/a | n/a |
| HQ | US | US |
Scroll horizontally to see both columns.
Common questions
Open the full decision support comparison
Differential diagnosis, treatment guidance, drug interactions, evidence-grounded Q&A. The CDS landscape ranges from the UpToDate gold standard to physician-only OpenEvidence. We compared what clinicians actually use.